Dendritic cell therapy of primary brain tumors

Molecular Medicine

Volumn 7, Issue 10, 2001, Pages 659-667

  Soling A ^a   Rainov, N G ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALTERNATIVE MEDICINE; ANTIGEN PRESENTATION; BRAIN TUMOR; CANCER THERAPY; DENDRITIC CELL; GENE THERAPY; GLIOBLASTOMA; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE; TUMOR IMMUNITY;

EID: 0035170517     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401956     Document Type: Review

References (56)

1. Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset
2. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells
3. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: Implications for immunotherapy
4. The induction of tolerance by dendritic cells that have captured apoptotic cells
5. Dendritic cell-based vaccines: From mouse models to clinical cancer immunotherapy
6. Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells
7. Dendritic cells: Multilineal and multi-functional
8. S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival
9. Peritumoral CD1a-positive dendritic cells are associated with improved survival in patients with tongue carcinoma
10. Vaccination with MAGE-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
11. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
12. Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial
13. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application
14. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
15. Report from the International Union Against Cancer (UICC) tumor biology committee
16. + progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells
17. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage
18. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection
19. The role of MHC class II-restricted tumor antigens and CD4+T cells in antitumor immunitiy
20. Migration of human dendritic cells after injection in patients with metastatic malignancies
21. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration
22. Clinical applications of dendritic cell vaccines
23. + T-cell in humans without foreign helper epitopes
24. Gene-modified dendritic cells for use in tumor vaccines
25. Viral vectors for dendritic cell-based immunotherapy
26. Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells
27. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction
28. Glioma immunology and immunotherapy
29. Exploitation of immune mechanisms in the treatment of central nervous system cancer
30. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas
31. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides
32. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-γ treatment
33. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
34. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
35. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semiliki Forest virus-mediated complementary DNA
36. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model
37. + T cells for efficient tumor cell lysis
38. Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells
39. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas
40. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
41. Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report
42. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
43. Dendritic cell immunotherapy for patients with glioblastoma multiforme and anaplastic astrocytoma
44. Gene therapy of malignant gliomas: A pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response
45. Sex- and stress-steroids interactions and the immune system: Evidence for a neuroendocrine-immunological sexual dimorphism
46. Generation of large numbers of immature and mature dendritic cells from rat bone marrow cultures
47. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
48. T cell activity after dendritic cell vaccination is dependent on both type of antigen and the mode of delivery
49. Dendritic cells injected via different routes induce immunity in cancer patients
50. Equipotent generation of protective antitumor immunity by various methods of dendritic cell loading with whole cell tumor antigens
51. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells
52. Induction of lethal experimental allergic encephalomyelitis in nonhuman primates and guinea pigs with human glioblastoma tissue
53. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells
54. Dendritic cells: On the move from bench to bedside
55. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine Interleukin-12
56. Cancer therapy using a self-replicating RNA vaccine